Base de dados : MEDLINE
Pesquisa : D02.241.081.114.968.500.500 [Categoria DeCS]
Referências encontradas : 1362 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 137 ir para página                         

  1 / 1362 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28216581
[Au] Autor:Vara-Gama N; Valladares-Méndez A; Navarrete-Vazquez G; Estrada-Soto S; Orozco-Castellanos LM; Rivera-Leyva JC
[Ad] Endereço:Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, 62209 Cuernavaca, Morelos, Mexico. nvara83@yahoo.com.mx.
[Ti] Título:Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat.
[So] Source:Molecules;22(2), 2017 Feb 14.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:In the current investigation, the physicochemical, biopharmaceutical and pharmacokinetic characterization of a new clofibric acid analog (Compound ) was evaluated. Compound showed affinity by lipophilic phase in 1 to 5 pH interval, indicating that this compound would be absorbed favorably in duodenum or jejunum. Also, Compound possess two ionic species, first above of pH 4.43 and, the second one is present over pH 6.08. The apparent permeability in everted sac rat intestine model was 8.73 × 10 cm/s in duodenum and 1.62 × 10 cm/s in jejunum, suggesting that Compound has low permeability. Elimination constant after an oral administration of 50 µg/kg in Wistar rat was 1.81 h , absorption constant was 3.05 h , C was 3.57 µg/mL at 0.33 h, AUC was 956.54 µ/mL·h and distribution volume was 419.4 mL. To IV administration at the same dose, ke was 1.21 h , Vd was 399.6 mL and AUC was 747.81 µ/mL·h. No significant differences were observed between pharmacokinetic parameters at every administration route. Bioavailability evaluated was 10.4%. Compound is metabolized to Compound probably by enzymatic hydrolysis, and it showed a half-life of 9.24 h. With these properties, Compound would be considered as a prodrug of Compound with potential as an antidiabetic and anti dyslipidemic agent.
[Mh] Termos MeSH primário: Ácido Clofíbrico/análogos & derivados
Tetrazóis/química
Tetrazóis/farmacocinética
[Mh] Termos MeSH secundário: Administração Intravenosa
Administração Oral
Animais
Disponibilidade Biológica
Cromatografia Líquida de Alta Pressão
Ácido Clofíbrico/farmacocinética
Duodeno/metabolismo
Meia-Vida
Hidrólise
Hipoglicemiantes/farmacocinética
Hipolipemiantes/farmacocinética
Absorção Intestinal
Jejuno/metabolismo
Masculino
Permeabilidade
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypoglycemic Agents); 0 (Hypolipidemic Agents); 0 (Tetrazoles); 53PF01Q249 (Clofibric Acid)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170504
[Lr] Data última revisão:
170504
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170221
[St] Status:MEDLINE


  2 / 1362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28068571
[Au] Autor:Chen P; Wang F; Zhang Q; Su Y; Shen L; Yao K; Chen ZF; Liu Y; Cai Z; Lv W; Liu G
[Ad] Endereço:School of Environmental Science and Engineering, Guangdong University of Technology, Guangzhou, 510006, China.
[Ti] Título:Photocatalytic degradation of clofibric acid by g-C N /P25 composites under simulated sunlight irradiation: The significant effects of reactive species.
[So] Source:Chemosphere;172:193-200, 2017 Apr.
[Is] ISSN:1879-1298
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Pharmaceutically emerging micropollutants have become an environmental concern in recent years. In the present paper, the reactive species (RSs)-induced degradation mechanism of clofibric acid (CA) was investigated using a newly sunlight-driven g-C N /P25 photocatalyst. A very low g-C N content of 8.0 weight percent resulted in a 3.36 and a 2.29 times faster reaction rate for CA photodegradation than for pristine g-C N and P25, respectively. Electron spin resonance and quenching experiments demonstrated the participation of HO, h , e , O and O in the photocatalytic system, and the contribution rates were calculated to 73.3%, 15.3%, 5.1%, 6.7% and 33.1%, respectively. According to the pulse radiolysis measurements and the competitive kinetics approaches, the bimolecular reaction rate constants for HO, e , and O with CA were (8.47 ± 0.33) × 10 M s , (6.41 ± 0.48) × 10 M s and (6.6 ± 0.37) × 10 M s , respectively. RSs were found to significantly influence the degradation of CA, and the degradation pathways occurred primarily via e reduction, HO addition and O attack reactions on the basis of mass spectrometry and theoretical calculations.
[Mh] Termos MeSH primário: Ácido Clofíbrico/química
Fotólise
Luz Solar
Poluentes Químicos da Água/química
[Mh] Termos MeSH secundário: Anticolesterolemiantes/química
Hipolipemiantes/química
Cinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Hypolipidemic Agents); 0 (Water Pollutants, Chemical); 53PF01Q249 (Clofibric Acid)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170110
[St] Status:MEDLINE


  3 / 1362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28063965
[Au] Autor:Danil de Namor AF; Al Nuaim M; Villanueva Salas JA; Bryant S; Howlin B
[Ad] Endereço:Laboratory of Thermochemistry, Department of Chemistry, University of Surrey, Guildford, Surrey GU2 7XH, United Kingdom. Electronic address: A.Danil-De-Namor@surrey.ac.uk.
[Ti] Título:A calix[4]arene derivative and its selective interaction with drugs (clofibric acid, diclofenac and aspirin).
[So] Source:Eur J Pharm Sci;100:1-8, 2017 Mar 30.
[Is] ISSN:1879-0720
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The synthesis and characterisation of a partially substituted calix[4]arene, namely, 5,11,17,23-tetra-tert-butyl,25,27-bis[aminoethoxy] 26,28-dihydroxycalix[4]arene are reported. Its interaction with commonly used pharmaceuticals (clofibric acid, diclofenac and aspirin) was investigated by spectroscopic ( H NMR and UV), electrochemical (conductance measurements) and thermal (titration calorimetry) techniques. It is concluded on the basis of the experimental work and molecular simulation studies that the receptor interacts selectively with these drugs. Preliminary studies on the selective extraction of these pharmaceuticals from water by the calix receptor are reported and the potential for a carrier mediated sensor based on this ligand for 'on site' monitoring of pharmaceuticals is discussed.
[Mh] Termos MeSH primário: Aspirina/química
Calixarenos/química
Ácido Clofíbrico/química
Diclofenaco/química
Fenóis/química
[Mh] Termos MeSH secundário: Calorimetria
Condutividade Elétrica
Modelos Moleculares
Espectroscopia de Prótons por Ressonância Magnética
Espectrofotometria Ultravioleta
Termodinâmica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Phenols); 0 (calix(4)arene); 130036-26-9 (Calixarenes); 144O8QL0L1 (Diclofenac); 53PF01Q249 (Clofibric Acid); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170703
[Lr] Data última revisão:
170703
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170109
[St] Status:MEDLINE


  4 / 1362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27215987
[Au] Autor:Manassero A; Satuf ML; Alfano OM
[Ad] Endereço:Instituto de Desarrollo Tecnológico para la Industria Química, Universidad Nacional del Litoral and Consejo Nacional de Investigaciones Científicas y Técnicas, Güemes 3450, 3000, Santa Fe, Argentina.
[Ti] Título:Photocatalytic degradation of an emerging pollutant by TiO -coated glass rings: a kinetic study.
[So] Source:Environ Sci Pollut Res Int;24(7):6031-6039, 2017 Mar.
[Is] ISSN:1614-7499
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:This work presents the photocatalytic degradation of the pharmaceutical drug clofibric acid in a fixed-bed reactor filled with TiO -coated glass rings. Experiments were carried out under UV radiation. A kinetic model that takes into account radiation absorption by means of the local surface rate of photon absorption (LSRPA) has been developed. The LSRPA was obtained from the results of a radiation model. The Monte Carlo method was employed to solve the radiation model, where the interaction between photons and TiO -coated rings was considered. Data from experiments carried out with rings with different numbers of catalyst coatings and different irradiation levels were used to estimate the parameters of the kinetic model. A satisfactory agreement was obtained between model simulations and experimental results.
[Mh] Termos MeSH primário: Ácido Clofíbrico
Vidro/química
Modelos Teóricos
Titânio/química
Poluentes Químicos da Água
[Mh] Termos MeSH secundário: Ácido Clofíbrico/análise
Ácido Clofíbrico/química
Ácido Clofíbrico/efeitos da radiação
Cinética
Fotólise
Poluentes Químicos da Água/análise
Poluentes Químicos da Água/química
Poluentes Químicos da Água/efeitos da radiação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Water Pollutants, Chemical); 15FIX9V2JP (titanium dioxide); 53PF01Q249 (Clofibric Acid); D1JT611TNE (Titanium)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171104
[Lr] Data última revisão:
171104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160525
[St] Status:MEDLINE
[do] DOI:10.1007/s11356-016-6855-2


  5 / 1362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27164891
[Au] Autor:Molina-Fernandez N; Perez-Conde C; Rainieri S; Sanz-Landaluze J
[Ad] Endereço:Department of Analytical Chemistry, Faculty of Chemical Science, Complutense University of Madrid, Avenida Complutense s/n, 28040, Madrid, Spain.
[Ti] Título:Method for quantifying NSAIDs and clofibric acid in aqueous samples, lumpfish (Cyclopterus lumpus) roe, and zebrafish (Danio rerio) eleutheroembryos and evaluation of their bioconcentration in zebrafish eleutheroembryos.
[So] Source:Environ Sci Pollut Res Int;24(12):10907-10918, 2017 Apr.
[Is] ISSN:1614-7499
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Pharmaceuticals such as nonsteroidal anti-inflammatory drugs (NSAIDs) and lipid regulators are being repeatedly detected at low concentrations (pg · mL -ng · mL ) in the environment. A large fraction of these compounds are ionizable. Ionized compounds show different physico-chemical properties and environmental behavior in comparison to their neutral analogs; as a consequence, the quantification methods currently available, based on the neutral molecules, might not be suitable to detect the corresponding ionized compounds. To overcome this problem, we developed a specific analytical method to quantify NSAIDs and lipid regulators (i.e., ibuprofen, diclofenac, naproxen, and clofibric acid) and their ionized compounds. This method is based on three steps: (1) the extraction of the organic compounds with an organic solvent assisted with an ultrasonic probe, (2) the cleaning of the extracts with a dispersive SPE with C , and (3) the determination of the chemical compounds by GC-MS (prior derivatization of the analytes). We demonstrated that the proposed method can successfully quantify the pharmaceuticals and their ionized compounds in aqueous samples, lumpfish eggs, and zebrafish eleutheroembryos. Additionally, it allows the extraction and the cleanup of extracts from small samples (0.010 g of wet weight in pools of 20 larvae) and complex matrixes (due to high lipid content) and can be used as a basis for bioaccumulation assays performed with zebrafish eleutheroembryos in alternative to OECD test 305.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/análise
Ácido Clofíbrico/análise
Perciformes
Poluentes Químicos da Água/análise
Peixe-Zebra
[Mh] Termos MeSH secundário: Animais
Embrião não Mamífero
Monitoramento Ambiental
Larva
Óvulo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Water Pollutants, Chemical); 53PF01Q249 (Clofibric Acid)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160512
[St] Status:MEDLINE
[do] DOI:10.1007/s11356-016-6671-8


  6 / 1362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27849333
[Au] Autor:Jakob T; Nordmann AJ; Schandelmaier S; Ferreira-González I; Briel M
[Ad] Endereço:Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland.
[Ti] Título:Fibrates for primary prevention of cardiovascular disease events.
[So] Source:Cochrane Database Syst Rev;11:CD009753, 2016 11 16.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Fibrates are effective for modifying atherogenic dyslipidaemia, and particularly for lowering serum triglycerides. However, evidence that fibrates reduce mortality and morbidity associated with cardiovascular disease (CVD), or overall mortality and morbidity, in the primary prevention of CVD is lacking. OBJECTIVES: This Cochrane Review and meta-analysis aimed to evaluate the clinical benefits and harms of fibrates versus placebo or usual care or fibrates plus other lipid-modifying drugs versus other lipid-modifying drugs alone for the primary prevention of cardiovascular disease (CVD) morbidity and mortality. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCO), and Web of Science (all from inception to 19 May 2016). We searched four clinical trial registers (last searched on 3 August 2016) with the help of an experienced professional librarian. We searched the databases to identify randomised controlled trials (RCTs) evaluating the clinical effects of fibrate therapy in the primary prevention of CVD events. We did not impose any language restrictions. SELECTION CRITERIA: We aimed to include all RCTs comparing the effects of fibrate monotherapy versus placebo or usual care, or fibrates plus other lipid-modifying drugs versus other lipid-modifying drugs alone. Included studies had a follow-up of at least six months for the primary prevention of CVD events. We excluded trials with clofibrate, because it was withdrawn from the market in 2002. DATA COLLECTION AND ANALYSIS: Two review authors independently screened titles and abstracts for potential study inclusion. Two review authors independently retrieved the full-text papers and extracted data. Disagreements were resolved by consensus. We calculated risk ratios (RRs) and accompanying 95% confidence intervals (CIs) for aggregate data on primary and secondary outcomes. We tested for heterogeneity with the Cochrane Q-test and used the I statistic to measure inconsistency of treatment effects across studies. Using the GRADE approach, we assessed the quality of the evidence and used the GRADE profiler software (GRADEpro GDT) to import data from Review Manager 5 to create 'Summary of findings' tables. MAIN RESULTS: We identified six eligible trials including 16,135 individuals. The mean age of trial populations varied across trials; between 47.3 and 62.3 years. Four trials included individuals with diabetes mellitus type 2 only. The mean treatment duration and follow-up of participants across trials was 4.8 years. We judged the risks of selection and performance bias to be low; risks of detection bias, attrition bias, and reporting bias were unclear. Reporting of adverse effects by included trials was very limited; that is why we used discontinuation of therapy due to adverse effects as a proxy for adverse effects. Patients treated with fibrates had a reduced risk for the combined primary outcome of CVD death, non-fatal myocardial infarction, or non-fatal stroke compared to patients on placebo (risk ratio (RR) 0.84, 95% confidence interval (CI) 0.74 to 0.96; participants = 16,135; studies = 6; moderate-quality of evidence). For secondary outcomes we found RRs for fibrate therapy compared with placebo of 0.79 for combined coronary heart disease death or non-fatal myocardial infarction (95% CI 0.68 to 0.92; participants = 16,135; studies = 6; moderate-quality of evidence); 1.01 for overall mortality (95% CI 0.81 to 1.26; participants = 8471; studies = 5; low-quality of evidence); 1.01 for non-CVD mortality (95% CI 0.76 to 1.35; participants = 8471; studies = 5; low-quality of evidence); and 1.38 for discontinuation of therapy due to adverse effects (95% CI 0.71 to 2.68; participants = 4805; studies = 3; I = 74%; very low-quality of evidence). Data on quality of life were not available from any trial. Trials that evaluated fibrates in the background of statins (2 studies) showed no benefits in preventing cardiovascular events. AUTHORS' CONCLUSIONS: Moderate-quality evidence suggests that fibrates lower the risk for cardiovascular and coronary events in primary prevention, but the absolute treatment effects in the primary prevention setting are modest (absolute risk reductions < 1%). There is low-quality evidence that fibrates have no effect on overall or non-CVD mortality. Very low-quality evidence suggests that fibrates are not associated with increased risk for adverse effects.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/prevenção & controle
Hipolipemiantes/uso terapêutico
Prevenção Primária
[Mh] Termos MeSH secundário: Atorvastatina Cálcica/uso terapêutico
Bezafibrato/uso terapêutico
Doenças Cardiovasculares/mortalidade
Ácido Clofíbrico/análogos & derivados
Ácido Clofíbrico/uso terapêutico
Fenofibrato/uso terapêutico
Genfibrozila/uso terapêutico
Seres Humanos
Hipolipemiantes/efeitos adversos
Meia-Idade
Infarto do Miocárdio/epidemiologia
Infarto do Miocárdio/mortalidade
Prevenção Primária/normas
Sinvastatina/uso terapêutico
Acidente Vascular Cerebral/epidemiologia
Acidente Vascular Cerebral/mortalidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Hypolipidemic Agents); 23TF67G79M (etofibrate); 48A5M73Z4Q (Atorvastatin Calcium); 53PF01Q249 (Clofibric Acid); AGG2FN16EV (Simvastatin); Q8X02027X3 (Gemfibrozil); U202363UOS (Fenofibrate); Y9449Q51XH (Bezafibrate)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161117
[St] Status:MEDLINE


  7 / 1362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27657658
[Au] Autor:Avetta P; Fabbri D; Minella M; Brigante M; Maurino V; Minero C; Pazzi M; Vione D
[Ad] Endereço:Università degli Studi di Torino, Dipartimento di Chimica, Via P. Giuria 5, 10125 Torino, Italy(1).
[Ti] Título:Assessing the phototransformation of diclofenac, clofibric acid and naproxen in surface waters: Model predictions and comparison with field data.
[So] Source:Water Res;105:383-394, 2016 Nov 15.
[Is] ISSN:1879-2448
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Phototransformation is important for the fate in surface waters of the pharmaceuticals diclofenac (DIC) and naproxen (NAP) and for clofibric acid (CLO), a metabolite of the drug clofibrate. The goal of this paper is to provide an overview of the prevailing photochemical processes, which these compounds undergo in the different conditions found in freshwater environments. The modelled photochemical half-life times of NAP and DIC range from a few days to some months, depending on water conditions (chemistry and depth) and on the season. The model indicates that direct photolysis is the dominant degradation pathway of DIC and NAP in sunlit surface waters, and potentially toxic cyclic amides were detected as intermediates of DIC direct phototransformation. With modelled half-life times in the month-year range, CLO is predicted to be more photostable than DIC or NAP and to be degraded mainly by reaction with the OH radical and with the triplet states of chromophoric dissolved organic matter ( CDOM*). The CLO intermediates arising from these processes and detected in this study (hydroquinone and 4-chlorophenol) are, respectively, a chronic toxicant to aquatic organisms and a possible carcinogen for humans. Hydroquinone is formed with only ∼5% yield upon CLO triplet-sensitised transformation, but it is highly toxic for algae and crustaceans. In contrast, the formation yield of 4-chlorophenol reaches ∼50% upon triplet sensitisation and ∼10% by OH reaction. The comparison of model predictions with field data from a previous study yielded a very good agreement in the case of DIC and, when using 4-carboxybenzophenone as proxy for triplet sensitisation by CDOM, a good agreement was found for CLO as well. In the case of NAP, the comparison with field data suggests that its direct photolysis quantum yield approaches or even falls below the lower range of literature values.
[Mh] Termos MeSH primário: Ácido Clofíbrico
Naproxeno
[Mh] Termos MeSH secundário: Diclofenaco
Cinética
Modelos Químicos
Fotólise
Poluentes Químicos da Água/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Water Pollutants, Chemical); 144O8QL0L1 (Diclofenac); 53PF01Q249 (Clofibric Acid); 57Y76R9ATQ (Naproxen)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160923
[St] Status:MEDLINE


  8 / 1362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27529207
[Au] Autor:Omar AM; Mahran MA; Ghatge MS; Bamane FH; Ahmed MH; El-Araby ME; Abdulmalik O; Safo MK
[Ad] Endereço:Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Alsulaymanyah, Jeddah 21589, Saudi Arabia. asmansour@kau.edu.sa.
[Ti] Título:Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin.
[So] Source:Molecules;21(8), 2016 Aug 13.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Hemoglobin (Hb) modifiers that stereospecifically inhibit sickle hemoglobin polymer formation and/or allosterically increase Hb affinity for oxygen have been shown to prevent the primary pathophysiology of sickle cell disease (SCD), specifically, Hb polymerization and red blood cell sickling. Several such compounds are currently being clinically studied for the treatment of SCD. Based on the previously reported non-covalent Hb binding characteristics of substituted aryloxyalkanoic acids that exhibited antisickling properties, we designed, synthesized and evaluated 18 new compounds (KAUS II series) for enhanced antisickling activities. Surprisingly, select test compounds showed no antisickling effects or promoted erythrocyte sickling. Additionally, the compounds showed no significant effect on Hb oxygen affinity (or in some cases, even decreased the affinity for oxygen). The X-ray structure of deoxygenated Hb in complex with a prototype compound, KAUS-23, revealed that the effector bound in the central water cavity of the protein, providing atomic level explanations for the observed functional and biological activities. Although the structural modification did not lead to the anticipated biological effects, the findings provide important direction for designing candidate antisickling agents, as well as a framework for novel Hb allosteric effectors that conversely, decrease the protein affinity for oxygen for potential therapeutic use for hypoxic- and/or ischemic-related diseases.
[Mh] Termos MeSH primário: Antidrepanocíticos/química
Hemoglobinas/química
[Mh] Termos MeSH secundário: Regulação Alostérica/efeitos dos fármacos
Antidrepanocíticos/síntese química
Antidrepanocíticos/farmacologia
Sítios de Ligação
Ácido Clofíbrico/química
Ácido Clofíbrico/farmacologia
Hemoglobinas/metabolismo
Modelos Moleculares
Conformação Molecular
Ligação Proteica
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antisickling Agents); 0 (Hemoglobins); 53PF01Q249 (Clofibric Acid)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170603
[Lr] Data última revisão:
170603
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160817
[St] Status:MEDLINE


  9 / 1362 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27476274
[Au] Autor:Francik R; Kryczyk J; Francik S
[Ti] Título:CORONARY EFFECT OF FIBRATES ON PROTEINS AND ENZYMES WHICH HYDROLYZE TRIACYLGLYCEROLS.
[So] Source:Acta Pol Pharm;73(3):579-88, 2016 May-Jun.
[Is] ISSN:0001-6837
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Clofibric acid derivatives called fibrates, are quite commonly used lipid-lowering drugs, so it is necessary to know beneficial and adverse effects of these compounds on the body. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that benefits of four fibrates such as: bezafibrate, ciprofibrate, fenofibrate and gemfibrozil continue outweigh their risk in treatment of people with blood lipid disorders. According to recommendations of the CHMP fibrates should not be used as first-line drugs, except in patients with severe hypertriglyceridemia and patients who cannot use statins. In this paper, we focused on effect of clofibric acid derivatives on lipid metabolism, in particular on apoproteins and regulatory enzymes.
[Mh] Termos MeSH primário: Ácido Clofíbrico/efeitos adversos
Ácido Clofíbrico/uso terapêutico
Vasos Coronários/efeitos dos fármacos
Vasos Coronários/enzimologia
Ácidos Fíbricos/efeitos adversos
Ácidos Fíbricos/uso terapêutico
Hipolipemiantes/efeitos adversos
Hipolipemiantes/uso terapêutico
Triglicerídeos/metabolismo
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Metabolismo dos Lipídeos/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Fibric Acids); 0 (Hypolipidemic Agents); 0 (Triglycerides); 53PF01Q249 (Clofibric Acid)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160801
[Lr] Data última revisão:
160801
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160802
[St] Status:MEDLINE


  10 / 1362 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27448753
[Au] Autor:Lu X; Shao Y; Gao N; Chen J; Zhang Y; Wang Q; Lu Y
[Ad] Endereço:State Key Laboratory of Pollution Control and Resource Reuse, College of Environmental Science and Engineering, Tongji University, Shanghai, China.
[Ti] Título:Adsorption and removal of clofibric acid and diclofenac from water with MIEX resin.
[So] Source:Chemosphere;161:400-411, 2016 Oct.
[Is] ISSN:1879-1298
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study demonstrates the use of MIEX resin as an efficient adsorbent for the removal of clofibric acid (CA) and diclofenac (DCF). The adsorption performance of CA and DCF are investigated by a batch mode in single-component or bi-component adsorption system. Various factors influencing the adsorption of CA and DCF, including initial concentration, contact time, adsorbent dosage, initial solution pH, agitation speed, natural organic matter and coexistent anions are studied. The Langmuir model can well describe CA adsorption in single-component system, while the Freundlich model gives better fitting in bi-component system. The DCF adsorption can be well fitted by the Freundlich model in both systems. Thermodynamic analyses show that the adsorption of CA and DCF is an endothermic (ΔH(o) > 0), entropy driven (ΔS(o) > 0) process and more randomness exists in the DCF adsorption process. The values of Gibbs free energy (ΔG(o) < 0) indicate the adsorption of DCF is spontaneous but nonspontaneous (ΔG(o) > 0) for CA adsorption. The kinetic data suggest the adsorption of CA and DCF follow the pseudo-first-order model in both systems and the intra-particle is not the unique rate-limiting step. The adsorption process is controlled simultaneously by external mass transfer and surface diffusion according to the surface diffusion modified Biot number (Bis) ranging from 1.06 to 26.15. Moreover, the possible removal mechanism for CA and DCF is respectively proposed based on the ion exchange stoichiometry.
[Mh] Termos MeSH primário: Ácido Clofíbrico/química
Diclofenaco/química
Resinas de Troca Iônica/química
Poluentes Químicos da Água/química
[Mh] Termos MeSH secundário: Adsorção
Concentração de Íons de Hidrogênio
Troca Iônica
Cinética
Temperatura Ambiente
Termodinâmica
Purificação da Água/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ion Exchange Resins); 0 (Water Pollutants, Chemical); 144O8QL0L1 (Diclofenac); 53PF01Q249 (Clofibric Acid)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160725
[St] Status:MEDLINE



página 1 de 137 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde